Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -4.16
- Piotroski Score 3.00
- Grade Buy
- Symbol (SANA)
- Company Sana Biotechnology, Inc.
- Price $2.63
- Changes Percentage (11.91%)
- Change $0.28
- Day Low $2.37
- Day High $2.67
- Year High $12.00
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/06/2025
- Fiscal Year End N/A
- Average Stock Price Target $8.00
- High Stock Price Target $8.00
- Low Stock Price Target $8.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.52
- Trailing P/E Ratio -4.59
- Forward P/E Ratio -4.59
- P/E Growth -4.59
- Net Income $-283,255,000
Income Statement
Quarterly
Annual
Latest News of SANA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Ron Insana: Bitcoin could be the mother of all manias as it soars toward $100,000
With bitcoin's price soaring towards $100,000, questions arise about its utility as a currency. Despite its rising market capitalization, bitcoin is yet to function effectively as an alternative curre...
By CNBC | 20 hours ago -
Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
The CEO mentions that specific patient numbers and biomarker data for XMT-1660 will be shared later this year. The company is exploring more frequent dosing schedules and assessing prior treatment his...
By Yahoo! Finance | 1 week ago -
Mersana Therapeutics Shares Climb 23% After 3Q Results Beat Estimates
Mersana Therapeutics' stock surged 23% as its loss decreased and Q3 results exceeded analyst estimates. The biopharmaceutical company's revenue rose to $12.6 million, with enough capital to support op...
By MarketWatch | 1 week ago
